How DNA Enhancer Hubs Drive Prostate Cancer Genes

Researchers at the Keck School of Medicine of USC have identified a 3D hierarchy of DNA “enhancers” that function as master switches for prostate cancer development. According to a study published in Genome Biology, these interconnected networks control gene expression, revealing potential new targets for precision cancer therapies that could move beyond current gene-specific treatments.

Mapping the 3D Architecture of Prostate Cancer

Scientists have long understood that enhancers—non-coding segments of DNA—regulate how genes switch on and off. However, new research led by Suhn Kyong Rhie, PhD, at the Keck School of Medicine of USC, demonstrates that these switches do not operate in isolation. By analyzing 201 datasets from both tumor samples and healthy prostate tissue, the team mapped how these elements fold into 3D networks.

The study identified 3,216 enhancers specific to prostate cancer. Using an advanced technique called Region Capture Micro-C, the researchers observed that these enhancers form physical, interconnected loops that are absent in healthy prostate cells. This structural shift allows cancer cells to hijack normal regulatory pathways to promote tumor growth.

The “Central Hub” Hierarchy

Not all enhancers hold the same influence within the genome. The research team utilized CRISPR technology to delete individual enhancers and track the resulting impact on cancer cell behavior. They discovered a clear hierarchy among these genetic switches.

Some enhancers act as “central hubs,” maintaining control over multiple cancer-promoting genes. When these master switches were deleted, the entire 3D network collapsed, significantly slowing the growth of cancer cells. In contrast, other enhancers played only minor, compensatory roles. According to Rhie, this distinction is critical because it identifies specific, high-leverage points within the genome that could be susceptible to therapeutic intervention.

Future Trends in Targeted Gene Therapy

The discovery of master regulatory switches points toward a shift in how clinicians might approach cancer treatment. Rather than targeting a single gene—which can often lead to drug resistance—future therapies could potentially edit these central enhancer hubs to shut down multiple disease-driving pathways simultaneously.

This approach has precedent. The FDA-approved therapy Casgevy already treats sickle cell disease and β-thalassemia by targeting an enhancer to modify gene expression. While the USC team emphasizes that their current findings are in the basic science stage, they suggest this model of “network editing” could eventually extend to breast cancer and other malignancies. Ongoing research in Rhie’s lab is currently investigating how these enhancer networks contribute to treatment resistance in existing cancer therapies.

Frequently Asked Questions

What are enhancers in the context of cancer?

Enhancers are non-coding DNA sequences that act as switches, turning genes on or off. In cancer, these switches become dysregulated, forming 3D networks that activate genes responsible for tumor growth.

Why is the “central hub” discovery important?

Identifying master switches allows researchers to see which parts of the genome control the most significant cancer-promoting functions. Targeting these hubs could be more effective than targeting individual genes.

Is this treatment available for patients now?

No. This research is currently in the basic science phase. While it provides a foundation for future gene-editing therapies, researchers must first understand the potential side effects of modifying these complex genetic networks.